5AM Ventures | Activity | F4

5AM Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

5AM Ventures participated in Nouscom's oversubscribed €120M ($135M) Series D financing, co-led by M Ventures and Revelation Partners, to fund NOUS-209 cancer interception therapy for Lynch Syndrome.

Nouscom

Nouscom 5AM Ventures

nouscom.com

OCT 19, 2026

OCT 19, 2026

Milestone

Rezera, a 5AM Ventures portfolio company, announced positive topline results from RESOLVE-1 Phase 2 trial of ruvonoflast (NLRP3 inhibitor) meeting its primary inflammation endpoint, with plans to initiate Phase 3 in PAD in H1 2027.

Rezera

Rezera 5AM Ventures

rezera.comSEP 9, 2026

SEP 9, 2026

Investment

5AM Ventures participated in a $68M PIPE financing as part of the Skye Bioscience/Redx Pharma transaction agreement, alongside Abingworth, British Business Bank, and NEXTBio Capital. The combined company will operate as Fibrx Therapeutics.

Skye Bioscience

Skye Bioscience 5AM Ventures

ir.skyebioscience.comAUG 14, 2026

AUG 14, 2026

Exit

Latigo Biotherapeutics, a 5AM Ventures portfolio company, priced its upsized IPO of 19.2M shares at $18.00/share for gross proceeds of $345.6M, trading on Nasdaq under ticker LTGO.

Latigo Biotherapeutics

Latigo Biotherapeutics 5AM Ventures

investors.latigobio.comAUG 6, 2026

AUG 6, 2026

Milestone

Kinaset Therapeutics, a 5AM Ventures portfolio company, announced first patient dosed in Phase 2b PANAIRAMA trial of frevecitinib (KN-002), an inhaled pan-JAK inhibitor, in patients with severe asthma.

Kinaset Therapeutics

Kinaset Therapeutics 5AM Ventures

kinasettherapeutics.comJUL 20, 2026

JUL 20, 2026

Exit

Portfolio company Crinetics Pharmaceuticals agreed to be acquired by Vertex Pharmaceuticals for $10 billion.

Crinetics

Crinetics 5AM Ventures

businesswire.comJUL 6, 2026

JUL 6, 2026

4 milestones· MAR 2026 – MAY 2026Show all

Milestone

Portfolio company Arvinas received FDA approval of VEPPANU (vepdegestrant) for advanced breast cancer.

Arvinas

Arvinas 5AM Ventures

ir.arvinas.comMAY 4, 2026

MAY 4, 2026

Milestone

Portfolio company Reprotech merged with TMRW Life Sciences to create comprehensive technology-enabled fertility cryostorage platform managing 1M+ specimens.

Reprotech

Reprotech 5AM Ventures

prnewswire.comAPR 2, 2026

reprotech.com

APR 2, 2026

Milestone

Independent Data Monitoring Committee recommended initiation of Cohort 2 in Entrada's ELEVATE-44-201 gene therapy trial at increased dose.

Entrada Therapeutics

Entrada Therapeutics 5AM Ventures

5amventures.comMAR 17, 2026

MAR 17, 2026

Milestone

Portal Instruments signed multi-million dollar development agreement to advance PRIME NEXUS large volume reusable autoinjector to clinical readiness.

Portal Instruments

Portal Instruments 5AM Ventures

5amventures.comMAR 17, 2026

MAR 17, 2026

Exit

Portfolio company Wildcat Discovery Technologies acquired by Swedish battery technology firm Holyvolt for $73M.

Wildcat Discovery Technologies

Wildcat Discovery Technologies5AM Ventures

holyvolt.comMAR 5, 2026

MAR 5, 2026

Milestone

NodThera appointed Geoff McDonough, M.D. as Chief Executive Officer.

NodThera

NodThera 5AM Ventures

5amventures.comFEB 4, 2026

FEB 4, 2026

Investment

Co-led Mendra's $82M Series A alongside OrbiMed and 8VC for rare disease therapeutics using AI.

Mendra

Mendra 5AM Ventures

fenwick.comJAN 21, 2026

finance.yahoo.com

JAN 21, 2026

Investment

Participated in Precede Biosciences' $83.5M Series B for next-generation precision diagnostics.

Precede Biosciences

Precede Biosciences 5AM Ventures

5amventures.comJAN 12, 2026

precede.bio

JAN 12, 2026

Page 1 of 2